Zenotech Laboratories Ltd

Zenotech Laboratories Ltd

₹ 61.2 -0.39%
24 May - close price
About

Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]

Key Points

Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products

  • Market Cap 373 Cr.
  • Current Price 61.2
  • High / Low 81.0 / 49.6
  • Stock P/E
  • Book Value 15.8
  • Dividend Yield 0.00 %
  • ROCE -9.08 %
  • ROE -12.2 %
  • Face Value 10.0

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 3.87 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -14.8% over last 3 years.
  • Debtor days have increased from 72.3 to 96.1 days.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2006 Sep 2006
2.83 5.27
4.30 3.98
Operating Profit -1.47 1.29
OPM % -51.94% 24.48%
0.10 0.23
Interest 0.30 0.45
Depreciation 0.12 0.34
Profit before tax -1.79 0.73
Tax % 0.00% 0.00%
-1.79 0.73
EPS in Rs 0.14
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
12 13 8 6 7
15 19 18 24 16
Operating Profit -3 -6 -10 -18 -9
OPM % -20% -49% -121% -292% -143%
0 9 2 5 2
Interest 1 2 3 1 2
Depreciation 0 2 3 3 3
Profit before tax -3 -1 -14 -18 -13
Tax % -6% 250% -17% -0% 0%
-4 2 -16 -18 -13
EPS in Rs 0.32 -2.64 -2.88 -2.05
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -20%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 29%
Stock Price CAGR
10 Years: 8%
5 Years: 23%
3 Years: 12%
1 Year: 19%
Return on Equity
10 Years: %
5 Years: %
3 Years: -15%
Last Year: -12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
Equity Capital 16 29 34 34 34
Reserves 6 25 92 74 62
31 36 19 17 10
21 10 8 5 4
Total Liabilities 74 100 153 131 111
16 60 61 62 71
CWIP 40 9 15 24 13
Investments 0 0 0 0 0
19 30 77 45 27
Total Assets 74 100 153 131 111

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
-16 -7 -3 -16 -10
-56 -15 -67 20 29
74 22 70 -4 -8
Net Cash Flow 2 -0 -0 1 11

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
Debtor Days 145 273 85 36 96
Inventory Days 139 331 575 172 279
Days Payable 451 455 421 226 253
Cash Conversion Cycle -167 149 240 -18 123
Working Capital Days 55 279 196 250 286
ROCE % 2% -9% -12% -9%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
0.00% 0.00% 0.00% 0.00% 0.00% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98%
31.15% 31.15% 31.15% 31.15% 31.15% 30.18% 30.17% 30.17% 30.18% 30.17% 30.17% 30.17%
No. of Shareholders 6,7647,2997,5667,7608,0147,9308,7469,1429,2499,5899,7629,819

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents